Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.

Clinical trial NCT07586904 · RECRUITING

Trial details

NCT number: NCT07586904
Sponsor: Xijing Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Melanoma (Skin Cancer)

Start date: 2025-05-01
Primary completion: 2026-12-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.